We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
Highlights Enhanced understanding of SCLC subtypes drives tailored treatment approaches. I...
Read ArticleAlive and Kicking is renowned biotech journo Tim Boreham’s new daily wrap covering morning movers an...
Read ArticleCynata Therapeutics flags three trial results in the short term for three different conditions, inc...
Read ArticleHighlights PTX-100 Phase 1b trial in r/r TCL has been completed with encouraging results. Phase...
Read ArticleHighlights Prescient Therapeutics has received AU$2.4 million as R&D Tax Incentive rebate fo...
Read ArticleHighlights PTX is advancing its diversified pipeline of cancer therapies, backed by a world-clas...
Read Article‘Big pay day’ for Prescient Therapeutics, says Pitt Street Aerometrex to benefit from the seismic s...
Read ArticleHighlights Prescient Therapeutics’ abstract for PTX-100 has been published on the American Socie...
Read ArticlePTX-100 Phase 1b study nearing completion; data to be reported at major haematology conference in...
Read ArticleAustralian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the e...
Read ArticleHighlights Abstract for the Phase 1b cancer trial results will be presented at the world’s large...
Read ArticlePrescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase...
Read ArticleAccording to the World Health Organisation (WHO), cancer is the leading cause of death globally. WHO...
Read ArticleClinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financ...
Read ArticleSteven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-...
Read ArticleTim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics. By Tim Bore...
Read ArticleOrphan diseases are those impacting less than 200,000 patients Orphan drug designation ensures an e...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage oncology com...
Read ArticleHighlights OmniCAR and CellPryme abstracts of Prescient have been accepted for showcasing at the...
Read ArticleHighlights Dr Ellen Feigal is serving on the Boards of NASDAQ-listed biotechnology companies Xen...
Read ArticleHighlights Prescient has informed about progress with regard to its PTX-100 therapy and cell the...
Read ArticleAmid the bombed-out biotech sector, early-stage developers of a new cancer immunotherapy have caught...
Read ArticleStockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and pickin...
Read ArticlePrescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive...
Read ArticleThis content is created by Smallcaps Authors. [Author : Filip Karinja] Clinical-stage oncology com...
Read ArticleTelix Pharma gets FDA approval Prescient shows good data from Phase 1b clinical trial Incannex plan...
Read ArticleHighlights Prescient Therapeutics (ASX:PTX) has updated on continued promising results in PTX-10...
Read ArticleShareCafeBig gains from tech and consumer discretionary boost ASX 0.05% by Peter Milios Australian...
Read ArticleASX 200 adds just 0.1% because it was literally the least it could do. Aussie tech stock surge nega...
Read ArticleThe granting of an Orphan Drug Designation for PTX-100 gives Prescient guaranteed market exclusivity...
Read ArticleShareCafeInformation Technology lifts ASX 0.1% at noon by Peter Milios Information Technology has...
Read ArticleThis content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage oncology com...
Read ArticleShareCafeStocks of the Hour: PTX, LIN, SLS Prescient Therapeutics (ASX:PTX)...
Read ArticleUS Food and Drug Administration (FDA) grants Prescient Therapeutics (PTX) broad orphan drug designat...
Read Article09 Mar 2023 - A snapshot of the stocks on the move featuring Prescient Therapeutics (ASX:PTX), Lindi...
Read ArticleHighlights Prescient Therapeutics’ PTX-100 therapy previously held Orphan Drug Designation (ODD)...
Read ArticleA little-known ASX biotech stock is setting the bar high today. In morning trade on Thursday, the A...
Read ArticleClinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced that the US F...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleHighlights Prescient Therapeutics’ latest half-year report focuses on progress made on its target...
Read ArticleHighlights Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened...
Read ArticleHighlights Prescient intends to modify the study protocol for enrolling additional CTCL patients...
Read ArticleHighlights Prescient marked a number of developments in 2022, cementing its lead in cancer thera...
Read ArticleHighlights: Prescient is developing a portfolio of targeted therapies and cell therapies for can...
Read ArticleStockhead’s Year in Review video series is a yearly wrap up address from company leaders showcasing...
Read ArticlePrescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notor...
Read ArticleA study by Prescient Therapeutics (ASX: PTX) into the effects of lead drug PTX-100 on relapsed and r...
Read Article27 new biotech companies listed on the ASX the last two years Australian companies need access to U...
Read ArticleAs the end of the day approaches, and with the benchmark struggling like a tired dog to keep its hea...
Read ArticleSPI Futures imply the ASX 200 will start the day 1% lower Wall St struggled on Friday despite/becau...
Read ArticleAussie markets end Friday on a -0.80% disappointment US signals new cannabis laws, good news for Au...
Read ArticleCAR-T therapy is leading the race as the holy grail to cure cancer but like many medical therapies i...
Read ArticleBiotechnology investing provides investors chance for capital growth and to do social good ticking...
Read ArticlePrescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th...
Read ArticlePrescient Therapeutics (PTX) unveils a novel adjuvant for enhancing cellular immunotherapyCellPryme-...
Read ArticleAt the world’s largest CAR-TCR meeting, Prescient Therapeutics (ASX: PTX) has debuted CellPryme-A, w...
Read ArticlePrescient will join with the US’s largest cancer centre with the goal of creating best-in-class, ada...
Read ArticlePrescient Therapeutics (ASX: PTX) has entered a strategic collaboration with the largest cancer cent...
Read ArticlePrescient Therapeutics (ASX: PTX) has entered a strategic collaboration with a renowned US cancer ce...
Read ArticlePrescient Therapeutics (PTX) partners with the largest cancer centre in the US to create best-in-cla...
Read ArticlePrescient’s work is being considered a game-changer in advancing CAR-T therapies for cancer treatmen...
Read ArticleGot 90 seconds? Then listen to CEO & managing director, Steven Yatomi-Clarke tell us about their...
Read ArticleClinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative c...
Read ArticlePrescient Therapeutics (ASX: PTX) has launched a capital raising targeting $8 million to maintain it...
Read ArticleClinical-stage oncology company developing personalised therapies Prescient Therapeutics (AS...
Read ArticleThe Prescient Therapeutics Ltd (ASX: PTX) share price is plunging during late afternoon trade on We...
Read ArticlePrescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to prog...
Read ArticlePrescient has joined forces with Thermo Fisher Scientific for a research program aiming to advance d...
Read ArticlePrescient Therapeutics (PTX) signs a deal with Thermo Fisher Scientific to accelerate the developme...
Read ArticleAustralian biotech Prescient Therapeutics (ASX: PTX) has signed an agreement with US-based pharmaceu...
Read ArticlePrescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical...
Read ArticleClinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement w...
Read ArticlePrescient Therapeutics (PTX) strikes a manufacturing services agreement with Q-Gen Cell Therapeutic...
Read ArticleShareCafeWebinar Recap – HPC, PTX, AR9 & MEK Catch up on the full webinar presentations from Th...
Read ArticleShareCafePrescient Therapeutics (ASX: PTX) – Webinar Presentation Steven Yatomi-Clarke – CEO &...
Read ArticleOncology company Prescient Therapeutics (PTX) focused on advancing its targeted and cell therapies...
Read ArticleSteven Yatomi-Clarke of Prescient Therapeutics speaks at the Switzer Small and Micro Cap Investor St...
Read ArticleThe granting of an Orphan Drug Designation by the US FDA will grant PTX-100 market exclusivity and o...
Read ArticlePrescient Therapeutics (PTX) receives orphan drug designation for its PTX-100 product for the treat...
Read ArticleStockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) per...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticlePrescient gets US patent approval Genetic Technologies expands EasyDNA into India and Europe Imrico...
Read ArticlePrescient Therapeutics (PTX) is granted a key US patent for its OmniCAR universal immune receptor (...
Read ArticlePrescient is continuing to be a powerful force in the burgeoning personalised cancer treatment thera...
Read ArticleClinical-stage oncology company Prescient Therapeutics (ASX: PTX) has today unveiled the latest tech...
Read ArticlePrescient Therapeutics (ASX:PTX) has announced the expansion of its Phase 1b clinical study...
Read ArticlePrescient Therapeutics (PTX) expands its clinical study of patients with relapsed and refractory ac...
Read ArticleXEC falls hard on Monday XOJ closes 1.2% lower Seafarms Group (ASX:SFG) recovers Friday losses A...
Read ArticleQuarterlies: A data dump of intrigue and a smidgen of smoke and mirrors. But while the pain is akin...
Read ArticlePrescient Thereapeutics gives hope with its personalised Car-T cell therapy Imugene working to acti...
Read ArticlePrescient Therapeutics (PTX) opens patient enrolments for an expanded phase 1B trial of its PTX-100...
Read ArticlePrescient Therapeutics (ASX: PTX) has begun recruiting for expanded clinical trial evaluating its dr...
Read ArticleInvestors have plenty of exciting updates to look forward as PTX advances clinical trials and its wo...
Read ArticleDisclosure: The authors of this article and owners of Next Investors, S3 Consortium Pty Ltd, and ass...
Read ArticleNew data published in the science journal Nature has supported clinical stage oncology company Presc...
Read ArticleClinical-stage oncology company Prescient Therapeutics (ASX: PTX) has announced it has ended the Dec...
Read ArticleWith around $15m in the bank, Prescient is pressing ahead to move its novel OmniCAR therapy into the...
Read ArticleIt’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19...
Read ArticleIt’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleIt’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19...
Read ArticleIt’s been another year of lockdown and supply challenges for all companies dealing with the COVID-19...
Read ArticleHe’s baaack! Fresh from founding and listing immune-oncology play Chimeric, Paul Hopper can add Radi...
Read ArticleThe new appointments will support Prescient’s ongoing and novel development of its Omnicar CAR-T the...
Read ArticleClinical stage oncology company Prescient Therapeutics (ASX: PTX) has made plans to advance and acce...
Read ArticleHighlights Despite pandemic, few ASX companies have delivered outstanding returns. LTR, ACB, P...
Read ArticleClinical-stage oncology company Prescient Therapeutics (PTX) eyes several milestones across its ant...
Read ArticlePrescient Therapeutics (ASX:PTX) is presenting new preclinical data on OmniCAR at the Cell a...
Read ArticlePrescient’s OmniCAR platform could overcome the limitations of CAR-T treatments for cancer and it’s...
Read ArticleClinical-stage oncology company Prescient Therapeutics (ASX: PTX) has revealed new data that demonst...
Read ArticlePrescient Therapeutics (PTX) will present new results this week for its OmniCAR drug at the Cell &a...
Read ArticleHighlights The ASX 200 was up 0.25% or 18.7 points to 7,361.3 at the open. Seven out of the 11...
Read ArticleThe S&P/ASX 200 index (ASX: XJO) has started the week in the red and is currently down 2% to 7,...
Read ArticleThe Prescient Therapeutics Ltd (ASX: PTX) share price has gained a further 5% to trade at 23 cents...
Read ArticleThe CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure canc...
Read ArticleSteven Yatomi-Clarke, the CEO & Managing Director of Prescient Therapeutics (PTX), speaks to Pet...
Read ArticleHighlights ASX-listed healthcare companies rarely fail to bring joy to the market participants,...
Read ArticleShareCafeA diversified portfolio of cancer treatment medicines Steven Yatomi-Clarke – CEO & Man...
Read ArticleShareCafeHidden Gems Webinar Recap – BPH, EX1, RAP & PTX Catch up on the full webinar with pres...
Read ArticleStockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and pickin...
Read ArticleThe appointment gives PTX a world-leading development team in the race to find solutions for next-ge...
Read ArticleClinical stage oncology company Prescient Therapeutics (ASX: PTX) has appointed brain cancer special...
Read ArticleGot 90 seconds? Then listen to CEO, Steven Yatomi-Clarke tell us about their company news. Prescient...
Read ArticleClinical-stage oncology company Prescient Therapeutics’ (ASX: PTX) strong cash position will enable...
Read ArticleThe Prescient Therapeutics Ltd (ASX: PTX) share price is off to the races, up 8% to 19.5 cents in e...
Read ArticlePrescient Therapeutics (ASX:PTX) says its cancer-fighting drug candidate has exhibited an excellent...
Read ArticleThe Prescient Therapeutics Ltd (ASX: PTX) share price is having a lacklustre day, despite a positiv...
Read ArticleThe Prescient Therapeutics Ltd (ASX: PTX) share price is soaring today, despite the company not rel...
Read ArticleShares in Prescient Therapeutics Ltd (ASX: PTX) have surged to fresh heights today on the back of n...
Read ArticleThe results significantly de-risk the project as PTX continues development of its OmniCAR platform. ...
Read ArticleWall Street at fresh record highs All three major US benchmarks closed on Friday at new record highs...
Read ArticleTragedy struck the CAR-T space this month with a US company halting a trial of its lead therapy afte...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleThe company will now proceed to its next phase of research at the world-leading Peter Mac cancer res...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleIt was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies relea...
Read ArticleThe federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tue...
Read ArticlePrescient Therapeutics (ASX:PTX) has announced a new research program with the Peter MacCall...
Read ArticleThe new CAR-T agreement for the OmniCAR platform adds to Prescient’s existing and related research p...
Read ArticleThe deal provides the ideal platform for Prescient to develop its OmniCAR product suite as part of b...
Read ArticleWith the number of days left to file March quarterly reports running a little short this month, it i...
Read ArticleWall Street wobbles on tax hike All three major indices in the US fell overnight, after a report say...
Read ArticleOur summary of Prescient Therapeutics Ltd's recent announcement What has happened? Prescient Therape...
Read ArticleSpecial Report: Australian biotech company Prescient Therapeutics (ASX:PTX) has announced what’s nex...
Read ArticleSummary Prescient Therapeutics announced three internal development programs related to unique O...
Read ArticleOur summary of Prescient Therapeutics Ltd's recent announcement What's happened? Prescient Therapeut...
Read ArticlePrescient Therapeutics CEO Steven Yatomi-Clarke speaks at the Switzer Small and Micro Cap Virtual In...
Read ArticleSummary Prescient Therapeutics has appointed Professor H. Miles Prince to its Scientific Advisor...
Read ArticleSummary Last 12 months have been fruitful for Prescient Therapeutics despite the challenges and...
Read ArticleSummary Prescient Therapeutics received new US Patent from the USPTO for companion diagnostic for...
Read ArticleSummary Prescient ended the September 2020 quarter with a cash balance of almost A$18.6 million f...
Read ArticleSummary Supported by an international leadership team with extensive expertise in cancer therapy,...
Read ArticlePrescient Therapeutics (ASX:PTX) has announced that it has received commitments to raise ove...
Read ArticleOn 26 August 2020, Prescient Therapeutics Limited (ASX:PTX) announced that it has received firm comm...
Read ArticleSpecial Report: Prescient Therapeutics has boosted its cash balance to $20.3m, leaving it well funde...
Read ArticleBiotech Prescient Therapeutics (ASX: PTX) has successfully raised $7 million to fund an expanded pip...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is putting down the pen and picking up th...
Read ArticleShareCafePrescient Therapeutics – ShareCafe Hidden Gems Webinar Presentation Presenter – Steven Y...
Read ArticleShareCafeHidden Gems Webinar Recap – JHL, PTX, LNU We continue to unearth small-cap companies as...
Read ArticlePrescient Therapeutics (ASX:PTX) has formed a cancer research partnership with the world-renowned Pe...
Read ArticlePrescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology...
Read ArticleSummary After demonstrating the safety at a dose of 1,000 mg/m2, Phase 1b study of PTX-100 will p...
Read ArticleSpecial Report: Biotech company Prescient Therapeutics is advancing to next-stage trials for its per...
Read ArticleAustralia based clinical-stage oncology company Prescient Therapeutics Limited (ASX:PTX) appointed g...
Read ArticleSummary Prescient Therapeutics’ Phase 1b trial with PTX-200 in AML progresses to the next dose le...
Read ArticlePrescient Therapeutics (ASX:PTX), The ASX-listed biotechnology player developing targeted and person...
Read ArticleMelbourne-based Prescient Therapeutics (ASX:PTX), a biotechnology company developing targete...
Read ArticleSummary In June 2020 quarter, Prescient added new assets in its belt with the most significant mi...
Read ArticleClinical stage oncology company Prescient Therapeutics Limited (ASX:PTX) notified that two of its as...
Read ArticleClinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets hav...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticlePrescient Therapeutics Limited (ASX:PTX) is a clinical-stage oncology company developing personalise...
Read ArticleWell-known for developing breakthrough targeted and personalised medicines approaches to treat cance...
Read ArticleThe company’s goal is to harness OmniCAR’s innate adaptability and control to develop novel cell the...
Read ArticleA quick wrap of the key winners and losers on Monday, June 1. Data is taken after the market closes...
Read ArticleBiotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil...
Read ArticleBiotech company Prescient Therapeutics (ASX: PTX) emerged from a trading halt this morning to unveil...
Read ArticleWant to know which stocks the fund managers have been putting their money in (and out) of? We’ve bee...
Read ArticleASX-listed Australia based clinical-stage oncology player Prescient Therapeutics Limited (ASX:PTX) i...
Read ArticleClinical trials are being shuttered in increasing numbers in Australia because of the challenges pos...
Read ArticlePrescient Therapeutics (ASX:PTX) says the Phase 1b study of PTX-100 will proceed to the next...
Read ArticleClinical stage oncology company Prescient Therapeutics (ASX: PTX) has confirmed a phase 1b basket st...
Read ArticleClinical trials are being shuttered in increasing numbers in Australia because of the risks posed by...
Read ArticleAustralian based clinical-stage Oncology company Prescient Therapeutics Limited (ASX:PTX), recently...
Read ArticleThe Coronavirus has become a health threat across the globe and as per World Health Organization (WH...
Read Article1 in 6 deaths is due to cancer As per World Health Organization, Cancer is the 2nd major cause of d...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company whi...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is an Australian based clinical-stage oncology company whi...
Read ArticleThe health sector was the most successful sector on the ASX in 2019. Various small caps made several...
Read ArticleIt’s fair to assume PainChek (ASX:PCK) shareholders are a happy bunch with a 12-month share price ri...
Read ArticleOncology company Prescient Therapeutics (ASX: PTX) has unveiled news of a high response rate to its...
Read ArticlePrescient Therapeutics (PTX) has reported a high response rate from its Phase 2a clinical trial for...
Read ArticleClinical stage oncology company engaged in developing personalised medicine approaches including tar...
Read ArticleWhether a day trader or a long-term investor, we often examine research released by industry experts...
Read ArticleOncology specialist company Prescient Therapeutics (ASX: PTX) has announced positive interim data fr...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) develops personalised medicine approaches to address mutat...
Read ArticleClinical-stage Oncology Company, Prescient Therapeutics Limited (ASX: PTX), that develops personalis...
Read ArticleShares in Prescient Therapeutics Limited (ASX:PTX) surged 50% on Wednesday after the clinical stage...
Read ArticleCancer drug developer Prescient Therapeutics (ASX: PTX) is expanding its Phase 1b study in patients...
Read ArticleFor a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Ove...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is involved in the development of breakthrough personalise...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company which is engaged in s...
Read ArticleOncology company Prescient Therapeutics (ASX: PTX) has unveiled a potentially lucrative collaboratio...
Read ArticleHeraMED’s (ASX:HMD) foetal ultrasound heart rate monitor has got its long awaited green light to ent...
Read ArticleStockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusB...
Read ArticleWith a focus on addressing mutations causing cancer, Prescient Therapeutics Limited (ASX: PTX) devel...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company focused on developing...
Read ArticleTo stay updated with PTX company activities and announcements, please update your details on their i...
Read Article“History is bunk!’’ declared industrialist Henry Ford, but unfortunately for the oro-mucosal deliver...
Read ArticleAustralian-headquartered global pharmaceutical leader, SUDA Pharmaceuticals Limited (ASX: SUD) is en...
Read ArticleYesterday, Trevor Hoey looked at the turnaround in the health services sector. He pointed out that t...
Read ArticleIn light of the volatility that has rocked global equities markets including the ASX, Finfeed felt i...
Read ArticleDrugs intake in the form of pills, capsules, and tablets are not the most efficient ways of taking m...
Read ArticleImugene Limited (ASX: IMU), an Australian-headquartered clinical-stage immuno-oncology company, focu...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is an Australian clinical stage oncology company that is i...
Read ArticleClinical stage oncology company, Prescient Therapeutics Limited (ASX: PTX) is engaged in developing...
Read ArticleAn oro-mucosal drug delivery company headquartered in Perth, SUDA Pharmaceuticals Ltd (ASX: SUD) use...
Read ArticlePrescient Therapeutics Limited (ASX: PTX) is a clinical-stage oncology company that works on mutatio...
Read ArticleClinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of devel...
Read ArticleOn 11 July 2019, Prescient Therapeutics Limited (ASX: PTX) announced the commencement of a Phase 1b...
Read ArticleAustralian company Prescient Therapeutics (ASX:PTX), a clinical-stage oncology company, has...
Read ArticleClinical stage oncology company Prescient Therapeutics Limited (ASX: PTX) is in the process of devel...
Read ArticleClinical-Stage oncology company, Prescient Therapeutics Limited (ASX: PTX) bases the foundation of i...
Read ArticleClinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
